/R E P E A T — Sirona Biochem Announces Discovery of Anti-Cellulite Activity in Compounds/

- September 22nd, 2021

Sirona Biochem Corp .   reports that In Vitro studies completed on compounds developed by our scientists at TFChem have shown a strong potential for anti-cellulite activity. The data showed evidence for both the ability to reduce existing cellulite and to prevent the formation of new cellulite. The mechanism of action is technically complex involving a pro-lipolytic effect, a decrease of the adipocyte size and an …

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (USOTC: SRBCF) (” Sirona “) reports that In Vitro studies completed on compounds developed by our scientists at TFChem have shown a strong potential for anti-cellulite activity. The data showed evidence for both the ability to reduce existing cellulite and to prevent the formation of new cellulite. The mechanism of action is technically complex involving a pro-lipolytic effect, a decrease of the adipocyte size and an anti-inflammatory effect.

Sirona’s Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy and her team have created a development plan and will begin the safety testing required for a clinical trial. Specific details of the compounds will be communicated immediately following the filing of patents.

Cellulite is the development of orange-peel like skin, particularly in the thigh and buttock area due to fat under the skin and often develops further with aging. There are currently no truly effective therapies to treat cellulite. The global market size was valued at USD 1.4 Billion in 2020 and is expected to have a compounded annual growth rate of 11.0%.

Additionally, as follow up to the last quarterly report , our pharmaceutical partner from the second clinical trial of TFC-1067 has successfully completed due diligence as scheduled. Follow up discussions are scheduled in September to discuss next steps with the goal of completing a long-term definitive agreement.

“We’re very excited about this discovery in a valuable market. Once again, the immense potential of our platform technology is demonstrated. Our scientist will conduct ongoing analysis of this discovery. At the same time management will continue to focus on our current priority initiative of further partnering TFC-1067,” said Dr. Howard Verrico , CEO. “With respect to 1067, we are pleased to be at an advanced stage following extensive due diligence and scientific research by our clinical trial partner. We are looking forward to next steps with great confidence.”

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

Cision View original content: http://www.newswire.ca/en/releases/archive/September2021/22/c3828.html

News Provided by Canada Newswire via QuoteMedia

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply